Current and resolved drug shortages and discontinuations reported to FDA, Food and Drug Administration (2024) Bydureon BCise highlights of prescribing information, Food and Drug Administration (2022) Ozempic highlights of prescribing information, Food and Drug Administration (2023) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with Type 2 diabetes (Sustain 3): A 56-week, open-label, randomized clinical trial, Diabetes Care (2018) Label: Bydureon BCise, DailyMed (2023) Label: Ozempic, Daily Med (2023) GLP-1 receptor agonists and the risk of thyroid cancer, Diabetes Care (2023) Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: A systematic review, Drug Safety (2024) The clinical efficacy and safety of glucagon-like peptide-1 (GLP-1) Agonists in adults with Type 2 diabetes mellitus, Clinical Medicine Insights: Endocrinology and Diabetes (2011) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
They are often described as sudden feelings of warmth, usually in the upper body, that can cause sweating and a flushed appearance
Patients who want FDA-reviewed data and predictable dosing often choose this option
As compared to Victoza (liraglutide), Ozempic has a three-fold lower attraction for the bodys GLP-1 receptor, but a much longer half-life
Ozempic/Wegovy (semaglutide) does not have a specific oral-contraceptive interaction warning, and pharmacokinetic studies showed no clinically meaningful effect on combined oral contraceptive levels
Important Safety Information What is the most important information I should know about Wegovy
